Phase 2 Stroke Trial, Recruiting NCT04903951 Sponsor: Philips Portuguesa S.A. Condition: Stroke
Back to Stroke

Phase 2 Stroke Trial, Recruiting

NCT04903951
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • A person who has given written agreement to take part (or whose legal representative has done so) before any study procedures begin.
  • People aged between 18 and 80 years old at the time of signing the consent form.
  • People who were admitted to hospital within 48 hours of their stroke symptoms starting.
  • People who have been diagnosed with their first-ever ischemic stroke (a stroke caused by a blocked blood vessel, not bleeding).
  • People whose stroke has caused a certain level of measurable impairment, based on a standard stroke severity scoring tool (confirm with trial site).
  • People who have been diagnosed with sleep apnea of at least a moderate level of severity, based on a standard breathing measurement (confirm with trial site).

Who may not be able to join:

  • People who have a specific type of sleep apnea related to the brain (central sleep apnea) combined with reduced heart pumping function (confirm with trial site).
  • People who were already using a breathing machine or device for sleep apnea before their stroke.
  • People who are considered at risk of inhaling food or fluid into their lungs.
  • People who have a feeding tube inserted through the nose and into the stomach.
  • People whose stroke was temporary (a TIA or "mini-stroke"), involved bleeding in the brain, or involved bleeding around the brain.
  • People whose stroke was caused by an underlying condition such as an abnormal blood vessel, blood vessel inflammation, a brain tumour, a head injury, or a tendency to bleed.
  • People who are in cardiorespiratory distress (serious breathing or heart difficulties).
  • People with a severe long-term lung condition that requires them to use supplemental oxygen.
  • People who have another condition affecting the brain or nervous system, such as dementia or multiple sclerosis.
  • People with uncontrolled psychosis or severe agitation.
  • People whose level of consciousness falls below a certain threshold on a standard assessment scale (confirm with trial site).
  • People with certain conditions affecting awareness or understanding of language (confirm with trial site).
  • People who do not have enough arm and hand function to manage a breathing mask and do not have a carer available overnight to assist.
  • People who are unable to take part in the hospital's rehabilitation program.
  • People who are pregnant or breastfeeding.
  • People who are already taking part in another clinical trial (participation in a standard-of-care registry may be acceptable — confirm with trial site).
  • People who, in the opinion of the trial investigator, are unsuitable for breathing support treatment for any other reason.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Sílvia Correia, MD, Trofa Saúde Hospital

Phone: 00351969043466

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Philips Portuguesa S.A.
Registry
ClinicalTrials.gov
Start date
27 February 2024
Est. completion
1 August 2025

Where this trial is recruiting

🇵🇹 Portugal

Primary endpoints

Proportion of patients with improvement in neurological parameters (reduction of ≥1 point from the beginning in Rankin scale) 1 month after stroke.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov